DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Jetstar to Charge for Overhead Cabin Bags From February 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Call Scheduled for Monday, March 19, 2018 at 4:30pm Eastern Time.
NEW YORK, March 13, 2018 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Monday, March 19, 2018.
| Conference Call & Webcast | ||||||
| Monday, March 19th @ 4:30pm Eastern Time | ||||||
| Domestic: | 800-289-0438 | |||||
| International: | 323-994-2083 | |||||
| Passcode: | 1979356 | |||||
| Webcast: | http://public.viavid.com/index.php?id=128779 | |||||
| Replays available through April 2: | ||||||
| Domestic: | 844-512-2921 | |||||
| International: | 412-317-6671 | |||||
| Conference ID: | 1979356 | |||||
| | ||||||
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
